Supported projects

H201901 – HIV vaccine approaches by genetic engineering of B-cells

Scientific leader
Dr. Anne Galy

New options are needed to vaccinate against deadly infectious agents such as HIV. Gene therapy could allow new vaccine approaches by precisely modifying the genome of human B lymphocytes (cells that naturally produce antibodies) by CRISPR molecular scissors. With this technique, it is thus possible to modify the specificity of immunoglobulin genes and to reprogram B cells to produce neutralizing antibodies against HIV-1. Still experimental, but recently confirmed by several laboratories, and supported by our preliminary data, this technique could become a powerful vaccine modality. We are equipping our ART platform (transfer research acceleration platform) with a MaxCyte electroporator and a protein imager to quickly implement preclinical protocols based on this new technology.



Accélérateur de Recherche Technologique en Thérapie Génomique (ART-TG) Inserm US-35

30 rue Henri Desbruères

91 100 Corbeil Essonnes